GlassScriptPhysician profile
Roy O Mears
NPI 1679733695
$406.98
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $227 · 2021: $40.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $83.05 | 2019-2020 | |
| Amgen INC. | $57.66 | 2019-2020 | |
| Allergan, INC. | $50.89 | 2020 | |
| Janssen Pharmaceuticals, INC | $38.31 | 2019-2020 | |
| Glaxosmithkline, LLC. | $31.18 | 2019-2020 | |
| Novo Nordisk INC | $31.12 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.24 | 2019-2021 | |
| Abbvie INC. | $28.84 | 2021 | |
| Pfizer INC. | $25.24 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.05 | 2020 | |
| Lilly USA, LLC | $11.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Mears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.